ClinicalTrials.gov record
Completed Phase 1 Interventional

Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or Relapsed Leukemia or Lymphoma

ClinicalTrials.gov ID: NCT00003079

Public ClinicalTrials.gov record NCT00003079. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 11, 2026, 9:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase I Study of Bryostatin 1 (NSC 339555) and High-Dose 1-Beta-D-Arabinofuranosylcytosine (HiDAC) in Patients With Refractory Leukemia

Study identification

NCT ID
NCT00003079
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Virginia Commonwealth University
Other
Enrollment
30 participants

Conditions and interventions

Interventions

  • bryostatin 1 Drug
  • cytarabine Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 1997
Primary completion
Apr 30, 2001
Completion
Apr 30, 2001
Last update posted
Feb 16, 2010

1997 – 2001

United States locations

U.S. sites
3
U.S. states
3
U.S. cities
3
Facility City State ZIP Site status
New York Presbyterian Hospital - Cornell Campus New York New York 10021
University of Texas - MD Anderson Cancer Center Houston Texas 77030
Massey Cancer Center Richmond Virginia 23298-0037

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00003079, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 16, 2010 · Synced May 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00003079 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →